Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection

Inclusion Criteria: * Willing to participate in the study and provide written informed consent * Male and female adults aged \> 18 years and less than 65 years * Must have had clinically suspected COVID-19 and a positive antibody test or a documented SARS-CoV-2 infection (a positive reverse transcription polymerase chain reaction test) at least 12 weeks prior to Screening * Must have fatigue-predominant PASC * Other than PASC, a subject must be in good health without other significant medical or not well controlled medical or psychiatric conditions Exclusion Criteria: * Other than PASC, have an explanation for fatigue * Other than PASC, a history or presence of an uncontrolled, clinically significant disease * Medical history that includes of Non-invasive or invasive ventilatory support for COVID 19, Intensive care unit or other high dependency unit admission for COVID-19, Hospitalization for \>1 week for COVID-19 without intubation